Does the addition of Recombinant Luteinising Hormone (recLH) (Luveris) to a regimen of Recombinant Follicle Stimulating Hormone (recFSH) (Gonal-F) and Gonadotropin Releasing Hormone (GnRH) antagonist (Cetrotide) improve ovarian response and implantation rates in patients age >35 years undergoing in vitro fertilisation (IVF)/embryo transfer (ET)?
Completed
- Conditions
- SubfertilityUrological and Genital DiseasesFemale infertility
- Registration Number
- ISRCTN10841210
- Lead Sponsor
- VU University Medical Centre (VUMC) (Netherlands)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 600
Inclusion Criteria
Age >35 years undergoing IVF or intracytoplasmic sperm injection (ICSI) for any indication
Exclusion Criteria
Women with polycystic ovary syndrome (PCOS)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method